



**KAREN GHEESLING MULLIS**

Vice President of R&D Project  
Management

Wugen Inc.

Dr. Gheesling Mullis has over 20 years of drug discovery, drug development, and investing experience in global pharmaceutical and drug biotech.

Prior to joining Wugen, Dr Gheesling Mullis was President of RiverVest's Archer Seed Venture Partners, L.L.C., investing in early stage biopharma companies.

From 1995-2016, Dr. Gheesling Mullis held increasingly responsible positions in research and development at Pfizer and heritage companies Searle/Pharmacia. She was an asset project manager in early and late clinical development programs from IND submissions through global submissions and new drug approvals, including IBRANCE® (palbociclib) for mBC and XALKORI® (Crizotinib) ROS1 + NSCLC. Dr. Gheesling Mullis holds a Ph.D. in Biochemistry at University of Alabama, Birmingham followed by a postdoctoral fellowship at Washington University, St. Louis in glycobiology. She also holds a Bachelor of Science in Chemistry from Emory University.